Annual report pursuant to Section 13 and 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)

v3.23.2
Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Balance $ 1,701,770    
Balance 1,966,516 $ 1,701,770  
Unrealized Gains (Losses) on Derivative Instruments      
Balance 8,069 (6,193) $ (13,253)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne 8,246 9,403 100
Reclassification from (gain) loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) (3,453) 4,859 6,960
Balance 12,862 8,069 (6,193)
Foreign Currency Translation Adjustments      
Balance (83,269) (51,098) (83,946)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne 4,191 (32,171) 32,848
Reclassification of cumulative translation adjustment for Eminence to non-operating income, net of taxes, attributable to Bio-Techne 152    
Balance (78,926) (83,269) (51,098)
Accumulated Other Comprehensive Income      
Balance (75,200) (57,291) (97,199)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne 12,437 (22,768) 32,948
Reclassification from (gain) loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) (3,453) 4,859 6,960
Reclassification of cumulative translation adjustment for Eminence to non-operating income, net of taxes, attributable to Bio-Techne 152    
Balance $ (66,064) $ (75,200) $ (57,291)